ABO‐incompatible liver transplantation: Is it a viable option with modern innovation?
Matthew B. Goss, Abbas Rana – 30 November 2017
Nonobese nonalcoholic fatty liver disease
Elizabeth Aby, Sammy Saab – 30 November 2017
Cardiac function, A key component in evaluation for liver transplant
Raquel Yotti, Cristina Ripoll, Javier Bermejo, Rafael Bañares – 29 November 2017
Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease
Yohei Masugi, Tokiya Abe, Hanako Tsujikawa, Kathryn Effendi, Akinori Hashiguchi, Masanori Abe, Yasuharu Imai, Keisuke Hino, Shuhei Hige, Miwa Kawanaka, Gotaro Yamada, Masayoshi Kage, Masaaki Korenaga, Yoichi Hiasa, Masashi Mizokami, Michiie Sakamoto – 27 November 2017 – Accurate staging of liver fibrosis is crucial to guide therapeutic decisions for patients with nonalcoholic fatty liver disease (NAFLD). Digital image analysis has emerged as a promising tool for quantitative assessment of fibrosis in chronic liver diseases.
Toward the elimination of hepatitis C in the United States
Sammy Saab, Long Le, Satvir Saggi, Vinay Sundaram, Myron J. Tong – 27 November 2017 – The emergence of effective direct‐acting antiviral (DAA) agents has reignited discussion over the potential for hepatitis C elimination in the United States. Eliminating hepatitis C will require a critical examination of technical feasibility, economic considerations, and social/political attention. Tremendous advancement has been made with the availability of sensitive diagnostic tests and highly effective DAAs capable of achieving sustained viral response (SVR) in more than 95% of patients.
Toward the elimination of hepatitis C in the United States
Sammy Saab, Long Le, Satvir Saggi, Vinay Sundaram, Myron J. Tong – 27 November 2017 – The emergence of effective direct‐acting antiviral (DAA) agents has reignited discussion over the potential for hepatitis C elimination in the United States. Eliminating hepatitis C will require a critical examination of technical feasibility, economic considerations, and social/political attention. Tremendous advancement has been made with the availability of sensitive diagnostic tests and highly effective DAAs capable of achieving sustained viral response (SVR) in more than 95% of patients.
Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial
Julie Thompson, Natasha Jones, Ali Al‐Khafaji, Shahid Malik, David Reich, Santiago Munoz, Ross MacNicholas, Tarek Hassanein, Lewis Teperman, Lance Stein, Andrés Duarte‐Rojo, Raza Malik, Talal Adhami, Sumeet Asrani, Nikunj Shah, Paul Gaglio, Anupama Duddempudi, Brian Borg, Rajiv Jalan, Robert Brown, Heather Patton, Rohit Satoskar, Simona Rossi, Amay Parikh, Ahmed ElSharkawy, Parvez Mantry, Linda Sher, David Wolf, Marquis Hart, Charles Landis, Alan Wigg, Shahid Habib, Geoffrey McCaughan, Steven Colquhoun, Alyssa Henry, Patricia Bedard, Lee Landeen, Michael Millis, Robert Ashley, William Frank
Who should receive endoscopic variceal ligation after recovering from acute variceal bleeding?
Xingshun Qi, Nahum Méndez‐Sánchez, Andrea Mancuso, Fernando Gomes Romeiro, Xiaozhong Guo – 24 November 2017
Acute acalculous cholecystitis during zika virus infection in an immunocompromised patient
Suzane Kioko Ono, Leda Bassit, Victor Van Vaisberg, Venâncio Avancini Ferreira Alves, Elia G. Caldini, Brian D. Herman, Reed Shabman, Nadia B. Fedorova, Denise Paranaguá‐Vezozzo, Caroline Torres Sampaio, Rafael Bandeira Lages, Débora Terrabuio, Wellington Andraus, Raymond F. Schinazi, Flair José Carrilho – 24 November 2017